Substained analgesia achieved with buprenorphine

A sustained release formulation of buprenorphine is new. The composition comprises a transdermal delivery device which provides a first order release of buprenorphine over a 3-day dosing interval so that a maximum plasma concentration of 20 10 1052 pg/ml is obtained. the device then provides zero or...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	REDER ROBERT F.,GOLDENHEIM PAUL D.,KAIKO ROBERT F
Format:	Patent
Sprache:	eng
Schlagworte:	BANDAGES, DRESSINGS OR ABSORBENT PADS DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROMTHE BODY DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF,TUBULAR STRUCTURES OF THE BODY, E.G. STENTS FILTERS IMPLANTABLE INTO BLOOD VESSELS FIRST-AID KITS FOMENTATION HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROSTHESES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TREATMENT OR PROTECTION OF EYES OR EARS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A sustained release formulation of buprenorphine is new. The composition comprises a transdermal delivery device which provides a first order release of buprenorphine over a 3-day dosing interval so that a maximum plasma concentration of 20 10 1052 pg/ml is obtained. the device then provides zero order kinetics over at least 2 more days.